The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE100100030
Funder
Australian Research Council
Funding Amount
$1,200,000.00
Summary
Advanced focused ion beam (FIB) / scanning electron microscopes (SEM) for nanometre scale characterisation and fabrication. These instruments are designed to provide fundamental insights into physical and biological systems though characterisation and fabrication of structures at nanometre length scales. These versatile platforms will support a wide range of projects covering three national research priority areas. These range from the characterisation of light alloys for improving and building ....Advanced focused ion beam (FIB) / scanning electron microscopes (SEM) for nanometre scale characterisation and fabrication. These instruments are designed to provide fundamental insights into physical and biological systems though characterisation and fabrication of structures at nanometre length scales. These versatile platforms will support a wide range of projects covering three national research priority areas. These range from the characterisation of light alloys for improving and building Australia's Aluminium, Magnesium and Titanium alloy industries, to the study of aerosol particles for improved pulmonary drug delivery for asthma patients, the development of advanced solar cells and the study of the integrated behaviour of the soil-microbe system for sustainable agriculture.Read moreRead less
Cardiovascular disease is a leading cause of death in Australia, accounting for 36% of all deaths in 2004-05. Diseased blood vessels are its most common form, and the underlying process is atherosclerosis. Atherosclerosis is characterised by plaque formation in blood vessels. Plaque formation is problematic, and may lead to blood vessel blockage. We aim to identify novel targets that prevent plaque formation.
Targeting The Achilles' Heel Of Polymyxins: Eliminating The Nephrotoxicity
Funder
National Health and Medical Research Council
Funding Amount
$673,420.00
Summary
The world is facing a growing threat from the emergence of bacterial 'superbugs' that are resistant to all current antibiotics except the polymyxins. However, kidney toxicity occurs in up to 60% of patients receiving intravenous polymyxins. In this project, we will examine how polymyxins cause kidney toxicity then employ the obtained mechanistic information to decrease this adverse effect. Our study targets the urgent global unmet medical need, lack of new antibiotics for bacterial ‘superbugs’.
Dissecting The Pathogenesis Of The Severe Neurodegenerative Disease, Friedreich’s Ataxia: Development Of Novel Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
Friedreich’s ataxia is a devastating neuro- and cardio-degenerative disorder which does not have an effective cure. The studies proposed in this Fellowship are crucial for understanding the progression of this disorder and the development of excitingly new therapeutics.
Industrial Transformation Research Hubs - Grant ID: IH190100021
Funder
Australian Research Council
Funding Amount
$4,999,540.00
Summary
ARC Research Hub to Combat Antimicrobial Resistance. The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users. The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR. A ....ARC Research Hub to Combat Antimicrobial Resistance. The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users. The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR. A goal of the Hub is to support the development of new molecular diagnostic technology, improve the processes for identifying potential antibiotic compounds and assess and advise on antimicrobial stewardship with a vision to transform social and health outcomes globally.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100177
Funder
Australian Research Council
Funding Amount
$150,000.00
Summary
A flexible high throughput analytical system for psychopharmacology and drug discovery. A sensitive new liquid chromatography mass spectrometer will enable a team of leading researchers to detect drugs of abuse and therapeutic drugs in the brain and body as well as levels of hormones, peptides and neurotransmitters. This will enhance a large number of projects examining new treatments for addictive disorders and mental illness.
Combating The Global Medical Challenge Caused By Gram-negative 'superbugs': From Redeveloping The Polymyxins To Discovering Novel Antibiotics
Funder
National Health and Medical Research Council
Funding Amount
$375,012.00
Summary
Bacterial �superbugs� are becoming a major global medical challenge. Polymyxins are the last-line antibiotics against Gram-negative �superbugs� but with little pharmacological information available. I am an antimicrobial pharmacologist specialised in re-developing polymyxins, and discovering novel antibiotics against these very troublesome bacteria. My research targets the _Bad Bugs, No Drugs� disaster highlighted by the Infectious Diseases Society of America and the World Health Organization.
Development Of A Unified List Of Drugs Associated With Drug-induced Cognitive Impairment
Funder
National Health and Medical Research Council
Funding Amount
$443,573.00
Summary
This research will develop a comprehensive list of drugs probably impairing cognition. These drugs will be identified from a large spontaneous reporting system in combination with those from published literature. The association of identified drugs and cognitive impairment will be tested using prescription sequence symmetry analyses in Pharmaceutical Benefits Scheme claims database and validated through formal epidemiological studies in Australian ongoing longitudinal population-based cohorts.
Contribution Of Complement C5a To Neuronal Cell Death During Ischemic Stroke
Funder
National Health and Medical Research Council
Funding Amount
$455,263.00
Summary
Ischemic stroke remains the second leading cause of death in Australia. This project aims to understand the role the innate immune system plays in neuronal cell death following ischemic stroke. We will use cellular and animal models of ischemic stroke, as well as examine patients affected by stroke, to explore and inhibit potential damaging immune factors generated by stroke tissue. By exploring these immune pathways, we aim to identify novel therapeutic targets to treat ischemic stroke.
Identifying And Exploiting Novel Pharmacological Targets For Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
Breast cancers are made up of different types of cancer cells, and not all cells contribute equally. A subset of cancer cells may be uniquely capable of driving tumor growth, rebuilding fatal tumors after therapy and establishing new tumors at distant sites. Identifying and exploiting the pathways that regulate the activity and survival of these cells will lead to better modes of treatment, and move towards a relapse-free future for breast cancer patients.